Status:
COMPLETED
PET/MRI and Biomarkers in Bladder Cancer
Lead Sponsor:
Turku University Hospital
Conditions:
Bladder Cancer
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Muscle invasive bladder cancer is an aggressive malignancy. Currently the investigators lack accurate imaging technologies in clinical staging and estimation of response to neoadjuvant chemotherapy as...
Eligibility Criteria
Inclusion
- invasive or locally advanced bladder cancer based on cystoscopic evaluation
- Age: 18 to 85 years old
- Language spoken: Finnish or Swedish
- Mental status: Patients must be able to understand the meaning of the study
- Informed consent: The patient must sign the appropriate Ethical Committee (EC) approved informed consent documents in the presence of the designated staff
Exclusion
- Prior medical history: Patient must have no history of serious cardiovascular, liver or kidney disease
- Infections: Patient must not have an uncontrolled serious infection
- Contraindications for MRI (cardiac pacemaker, intracranial clips etc)
- Patient refusing radical cystectomy or chemotherapy
- Intravesical Bacillus Calmette-Guerin instillations within 6 months
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2016
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01918592
Start Date
August 1 2013
End Date
November 1 2016
Last Update
April 18 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Hospital
Helsinki, Finland
2
Tampere University Hospital
Tampere, Finland
3
Turku University Hospital
Turku, Finland, 20100